Anastrozole ODF + Arimidex tablet + Anastrozole ODF + Arimidex tablet

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Safety

Conditions

Safety, Pharmacokinetics

Trial Timeline

Apr 1, 2012 โ†’ Jun 1, 2012

About Anastrozole ODF + Arimidex tablet + Anastrozole ODF + Arimidex tablet

Anastrozole ODF + Arimidex tablet + Anastrozole ODF + Arimidex tablet is a phase 1 stage product being developed by AstraZeneca for Safety. The current trial status is completed. This product is registered under clinical trial identifier NCT01568281. Target conditions include Safety, Pharmacokinetics.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01568281Phase 1Completed